Blood and Blood Components Market Analysis & Forecast: 2026-2033
The Blood and Blood Components Market size is anticipated to grow at a CAGR of 4.7% with USD 51.3 Bn in 2026 and is expected to reach USD 70.8 Bn in 2033. The market growth is primarily driven by the increasing prevalence of chronic diseases, rising number of surgical procedures and trauma cases, growing demand for blood transfusions, and expanding healthcare infrastructure across developing economies. According to the World Health Organization (WHO) Global Status Report on Blood Safety and Availability 2025, about 120.4 million units of blood were donated worldwide, out of which more than 85% were from voluntary non-remunerated donors.
On the basis of product type, the Blood Components segment is projected to account for the largest Blood and Blood Components Market share of 81.5% in 2026 The expansion of this sector is attributed to the extensive use of component therapy, which allows healthcare professionals to provide red blood cells, plasma, platelets, and white blood cells on a patient-specific basis, thus maximizing the use of blood.
According to the WHO Blood Safety and Availability Fact Sheet (June 2026), approximately 21.5 million litres of plasma from 36 reporting countries were fractionated for the production of plasma-derived medicinal products during the reporting year, including around 27% of plasma recovered from whole blood donations.
In March 2025, Grifols completed the acquisition of 14 U.S. plasma donation centers from Immunotek, expanding its vertically integrated plasma collection network.
To learn more about this report, Request Free Sample
On the basis of application, the Trauma and Surgery segment is projected to lead with a 34.2% share in 2026. The segment’s growth is owing to the increasing number of emergency trauma cases, major surgical procedures, organ transplantations, and accident-related hospitalizations requiring significant blood transfusion support.
According to the Global Guidelines for Intraoperative Blood Management (2024), it is projected that there are about 313 million surgeries conducted annually around the world, and 4.2 million people (7.7%) lose their lives within the first 30 days of their surgical procedures.
In April 2025, Baxter International announced the launch of the room temperature variant of HEMOPATCH Sealing Hemostat in Europe. This collagen-based sealing hemostat helps in controlling the flow of blood and minimizes fluid loss during surgery while providing easier storage and quick availability in the operating theater.
On the basis of end user, the Hospitals segment is projected to account for the largest Blood and Blood Components Market share of 67.4% in 2026. The segment’s growth is owing to the high volume of inpatient procedures, emergency care services, intensive care treatments, trauma management, and specialized surgeries performed in hospital settings, making hospitals the primary consumers of blood and blood components.
According to the World Health Organization (WHO) Blood Safety and Availability Fact Sheet (updated June 2026), only 40% of hospitals performing blood transfusions have hospital transfusion committees, while 68% have systems for reporting adverse transfusion events.
In February 2025, Abbott highlighted the role of its Alinity i System in enhancing blood screening accuracy and efficiency for blood banks and laboratories.
The increasing prevalence of anemia, hematological disorders, and chronic diseases is significantly driving demand for blood and blood components worldwide. Red blood cells, platelets, and plasma have wide applications in the treatment of anemia, leukemia, lymphoma, sickle cell anemia, thalassemia, and other diseases associated with the blood. The increasing number of patients requiring frequent blood transfusions has significantly increased the demand for blood components.
As per the WHO update of 2025, anemia affects about 40% of children between the ages of 6 and 59 months, 37% of pregnant women, and 30% of women between the ages of 15 and 49 years worldwide, thus ranking as one of the most common diseases needing treatment involving blood.
In October 2025, Terumo Blood and Cell Technologies announced a strategic investment in Hemex Health in order to increase the availability of diagnostic testing and patient care related to sickle cell disease and other hemoglobinopathies.
The increased number of surgical cases, injuries, transplantation of organs, and emergencies is expected to drive the demand for blood and its components significantly. Contemporary healthcare depends heavily on red blood cells, plasma, and platelets to control blood loss associated with major surgeries and other treatments. Increased investment in the field of healthcare and access to surgical procedures will contribute further to the growth of the market.
According to the WHO estimate that more than 310 million major surgeries take place annually worldwide, showing the high requirements of blood products during such operations.
In March 2025, Octapharma announced positive Phase III FARES-II trial results demonstrating that its four-factor Prothrombin Complex Concentrate (4F-PCC) was superior to frozen plasma in managing excessive bleeding during cardiac surgery.
|
Current Event |
Description and its Impact |
|
WHO Launches Global Initiative to Improve Anaemia Measurement and Diagnosis (February 2025) |
|
|
Terumo Blood and Cell Technologies Expands Automated Blood Component Processing (January 2025) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
The North America region will hold a market share of 39.8% in 2026. The growth of the North America region is due to the established system of blood collection facilities, high healthcare costs, advanced transfusion medicine practices, high number of blood banks, and use of blood component therapy. The growing number of surgeries, trauma cases, transplantations, and plasma products are driving the market growth in the North America region.
Based on the World Health Organization (WHO) Fact Sheet on Blood Safety and Availability (updated June 2026), wealthy countries contribute about 36% of the total blood donations worldwide even though they make up merely 15% of the total population.
In June 2025, America's Blood Centers launched Blood Advocacy Week 2025 and brought over 100 organizations from the U.S. healthcare industry to persuade the Congress to improve America’s blood supply system.
Asia Pacific is anticipated to experience rapid growth in the market for Blood and Blood Components during the forecast period. This is attributed to factors such as improvement in healthcare facilities in the region, increase in awareness regarding voluntary blood donation, high prevalence of anemia and hematology disorders, growing number of surgeries and government efforts to develop national blood transfusion services in countries including China, India, Japan, and South Korea.
According to the World Health Organization Global Status Report on Blood Safety and Availability 2025 released in June 2026, the South-East Asia Region witnessed one of the highest achievements of voluntary, unpaid blood donation over the last ten years owing to enhanced national blood programs, donor mobilization, and quality management systems in the region’s countries.
In June 2025, the Ministry of Health and Family Welfare conducted a national survey of the status of blood transfusion services in all states and union territories, assessing the process of blood collection, testing, processing, storage, distribution, and reporting based on data available through eRaktKosh, BBMS, CDSCO, and state level regulatory agencies.
The U.S. Blood and Blood Components Market continues to grow due to the efficient blood collection infrastructure, superior transfusion medicine technology, rising number of surgeries, and widespread use of blood component therapy. Consistent development in blood safety, donor mobilization, and laboratory automation systems are helping enhance the existing blood supply chain in the country.
As per the data provided by the American Red Cross (2025), the organization provides roughly 40% of the total blood and blood components in the country. In addition, an average of almost 29,000 units of red blood cells, around 6,500 units of platelets, and roughly 5,000 units of plasma are required each day in the country.
In December 2025, Cerus Corporation announced a Group Purchasing Agreement (GPA) with Blood Centers of America, the largest blood supply cooperative in the United States.
The China Blood and Blood Components Market is driven by increasing healthcare expenditure, modernization of blood banks, increasing incidences of chronic diseases, and various government efforts aimed at encouraging voluntary blood donations. There are also increasing investments in blood components collection, automation of laboratories, and processing of blood components.
According to the National Health Commission (NHC) of China, released in June 2025, China's blood donation rate reached 11.4 donations per 1,000 population. The NHC also stated that the country has established a nationwide voluntary blood donation system, strengthened blood screening technologies, and implemented cross-regional blood allocation mechanisms to ensure a safe and stable blood supply.
Some of the major key players in Blood and Blood Components Market are Becton, Dickinson & Co., Kidde-Fenwal Inc., Bio-Rad Laboratories, Inc., Cerus Corporation, Immucor, Beckman Coulter, Inc., bioMérieux SA, Octapharma AG, Abbott, CSL Behring LLC, MacoPharma, Shanghai RAAS, China Biologic Products Holdings, Inc., Takeda Pharmaceutical Company Limited, Grifols S.A., Bharat Serums and Vaccines Ltd., and Terumo BCT Inc.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 51.3 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.7% | 2033 Value Projection: | USD 70.8 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Becton, Dickinson & Co., Kidde-Fenwal Inc., Bio-Rad Laboratories, Inc., Cerus Corporation, Immucor, Beckman Coulter, Inc., bioMérieux SA, Octapharma AG, Abbott, CSL Behring LLC, MacoPharma, Shanghai RAAS, China Biologic Products Holdings, Inc., Takeda Pharmaceutical Company Limited, Grifols S.A., Bharat Serums and Vaccines Ltd., and Terumo BCT Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
